Literature DB >> 10764671

C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons.

J Gussekloo1, M C Schaap, M Frölich, G J Blauw, R G Westendorp.   

Abstract

An elevated level of C-reactive protein is a strong predictor of cardiovascular events in elderly persons. Whether C-reactive protein has direct adverse vascular effects or is a marker of aspecific systemic inflammation remains to be determined. The aim of this study was to investigate the relation between C-reactive protein and the occurrence of fatal strokes in elderly persons. In the Leiden 85-Plus Study, a population-based prospective follow-up study, we studied the levels of C-reactive protein in 80 participants who died from stroke within the first 5 years of follow-up. Levels of C-reactive protein were determined in serum samples at baseline. Levels of C-reactive protein were also determined in 82 control subjects who survived for the first 5 years of follow-up and in 83 participants who died from noncardiovascular causes. Mortality risks were estimated with logistic regression and adjusted for differences in age, sex, smoking, medication, total cholesterol, history of diabetes or hypertension, and previous cardiovascular events. Levels of C-reactive protein at baseline were 2-fold higher in subjects who died from stroke than in control subjects (median 5.7 versus 2.7 mg/L, P<0.005). The levels of C-reactive protein in subjects who died from stroke or from noncardiovascular causes were similar (median 5.7 versus 4.9 mg/L, P=0.7). The risk of death from stroke as well as from noncardiovascular causes increased linearly up to 10-fold in subjects with the highest levels of C-reactive protein at baseline (P<0.001). The levels of C-reactive protein were lower when more time had elapsed between blood sampling and time of death during follow-up (P=0.01). C-reactive protein is a strong but nonspecific risk factor of fatal stroke in old persons. The data do not support the idea that C-reactive protein has direct vascular effects that underlie fatal cerebrovascular disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764671     DOI: 10.1161/01.atv.20.4.1047

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  28 in total

Review 1.  C-reactive protein and risk of cardiovascular disease: evidence and clinical application.

Authors:  Paul M Ridker; Shari S Bassuk; Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 2.  Inflammatory mechanisms of stroke.

Authors:  Mitchell S V Elkind
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

3.  Common variants in the CRP gene in relation to longevity and cause-specific mortality in older adults: the Cardiovascular Health Study.

Authors:  Lucia A Hindorff; Kenneth M Rice; Leslie A Lange; Paula Diehr; Indrani Halder; Jeremy Walston; Pui Kwok; Elad Ziv; Caroline Nievergelt; Steven R Cummings; Anne B Newman; Russell P Tracy; Bruce M Psaty; Alexander P Reiner
Journal:  Atherosclerosis       Date:  2007-09-21       Impact factor: 5.162

Review 4.  The use of high-sensitivity assays for C-reactive protein in clinical practice.

Authors:  Kiran Musunuru; Brian G Kral; Roger S Blumenthal; Valentin Fuster; Catherine Y Campbell; Ty J Gluckman; Richard A Lange; Eric J Topol; James T Willerson; Milind Y Desai; Michael H Davidson; Samia Mora
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-08-19

5.  The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke.

Authors:  M S V Elkind; J M Luna; C S Coffey; L A McClure; K M Liu; S Spitalnik; M C Paik; A Roldan; C White; R Hart; O Benavente
Journal:  Int J Stroke       Date:  2010-04       Impact factor: 5.266

6.  The vascular effects of infection in Pediatric Stroke (VIPS) Study.

Authors:  Heather J Fullerton; Mitchell S V Elkind; A James Barkovich; Carol Glaser; David Glidden; Nancy K Hills; Carlos Leiva-Salinas; Max Wintermark; Gabrielle A Deveber
Journal:  J Child Neurol       Date:  2011-05-25       Impact factor: 1.987

7.  Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.

Authors:  Jessica L Mega; David A Morrow; Christopher P Cannon; Sabina Murphy; Richard Cairns; Paul M Ridker; Eugene Braunwald
Journal:  J Thromb Thrombolysis       Date:  2006-08       Impact factor: 2.300

Review 8.  Statin therapy in the elderly: does it make good clinical and economic sense?

Authors:  Moira M B Mungall; Allan Gaw; James Shepherd
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.

Authors:  Mitchell S V Elkind; Jorge M Luna; Leslie A McClure; Yu Zhang; Christopher S Coffey; Ana Roldan; Oscar H Del Brutto; Edwin Javier Pretell; L Creed Pettigrew; Brett C Meyer; Jorge Tapia; Carole White; Oscar R Benavente
Journal:  Stroke       Date:  2014-02-12       Impact factor: 7.914

10.  Supplementation with tocotrienol-rich fraction alters the plasma levels of Apolipoprotein A-I precursor, Apolipoprotein E precursor, and C-reactive protein precursor from young and old individuals.

Authors:  Eng Chee Heng; Saiful Anuar Karsani; Mariati Abdul Rahman; Noor Aini Abdul Hamid; Zalina Hamid; Wan Zurinah Wan Ngah
Journal:  Eur J Nutr       Date:  2013-01-04       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.